Targeting the AKT/PI3K signaling pathway has been proposed as an effective therapeutic approach for patients with HNSCC since its suppression has been shown to trigger cell cycle arrest and apoptosis (28). This evidence concerns the gene AKT1 and head and neck squamous cell carcinoma.